Jose Vinagre, MD
Internal Medicine · Indian Orchard, MANPI 1053329045
Payments from drug & device makers
Across 691 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Pfizer$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$805
- GSK$671
- plus $5K from 31 others
What the payments were for
- Food & beverage$12,20799%
- Education$1221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 111 | $2,296 |
| Pfizer | 105 | $1,344 |
| Novo Nordisk | 70 | $1,297 |
| Lilly USA, LLC | 69 | $1,198 |
| Boehringer Ingelheim | 47 | $805 |
| GSK | 40 | $671 |
| Abbott | 29 | $597 |
| Merck | 29 | $493 |
| Johnson & Johnson | 31 | $485 |
| Exact Sciences | 23 | $440 |
| Novartis | 21 | $377 |
| E.r. Squibb & Sons, L.L.C. | 19 | $344 |
| AbbVie(2 entities) | 18 | $340 |
| Astellas Pharma US Inc | 12 | $327 |
| Sanofi-aventis U.S. LLC | 15 | $305 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $175 |
| Baxter Healthcare | 3 | $125 |
| Dexcom, Inc. | 4 | $93 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $68 |
| Corium, LLC | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 4 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $51 |
| Amarin Pharma, Inc. | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Tactile Systems Technology Inc | 2 | $34 |
| Bayer | 1 | $32 |
| Indivior Inc. | 1 | $28 |
| Amgen | 2 | $27 |
| Eisai Inc. | 1 | $25 |
| Valeritas, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Vertex | 1 | $21 |
| Ardelyx, Inc. | 1 | $21 |
| Lifescan, Inc. | 1 | $20 |
| Alk-abello, Inc | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$12,329 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 135 | $153,790 |
| FarxigaDapagliflozin Propanediol | 63 | $65,275 |
| OzempicSemaglutide | 36 | $35,261 |
| JanuviaSitagliptin Phosphate | 19 | $22,440 |
| JardianceEmpagliflozin | 16 | $19,574 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $19,451 |
| LinzessLinaclotide | 16 | $19,449 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $15,776 |
| TrulicityDulaglutide | 15 | $15,546 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 80 | $12,486 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $11,587 |
| Atorvastatin Calcium | 730 | $11,421 |
| Serevent DiskusSalmeterol Xinafoate | 14 | $10,431 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $10,385 |
| OxycontinOxycodone Hcl | 24 | $10,350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,344 | $153,790135 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,296 | $74,36377 claims |
| MerckJanuvia, Janumet | $493 | $38,21634 claims |
| Novo NordiskOzempic | $1,297 | $35,26136 claims |
| Boehringer IngelheimJardiance | $805 | $19,57416 claims |
| GSKTrelegy Ellipta | $671 | $19,45111 claims |
| AbbVieLinzess | $340 | $19,44916 claims |
| Lilly USA, LLCTrulicity | $1,198 | $15,54615 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $51 | $7,53016 claims |
| Sanofi-aventis U.S. LLCAvapro | $305 | $3,24312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Indian Orchard
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
- Ryan SullivanCambridge$8.5M
- Xiuning leBoston$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.